Vol 10: A clinician-s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation - full speed ahead or proceed with cautionReport as inadecuate



 Vol 10: A clinician-s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation - full speed ahead or proceed with caution


Vol 10: A clinician-s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation - full speed ahead or proceed with caution - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 10: A clinician-s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation - full speed ahead or proceed with caution
This article is from Vascular Health and Risk Management, volume 10.AbstractOver the past few years, three novel oral anticoagulants, dabigatran, rivaroxaban, and apixaban, have been approved in the USA and Europe to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, and the results of a Phase III trial

Author: Yang, Eugene

Source: https://archive.org/



DOWNLOAD PDF




Related documents